Our journey

Recognition, funding and regulatory roadmap of Zamenis Biotech Innovation.

Roadmap

Regulatory roadmap: Peru, Chile and Japan

We are building the regulatory path in the three countries where we validate and project MABIS. No health authorization has been obtained yet.

Peru (home base)

Phase 2 at AUNA and IREN-SUR clinics; filing in preparation for DIGEMID.

Chile

Priority target market. Regulatory path initiated toward health registration with the ISP. Seeking local clinical partnerships. Prior recognition: the Chile Breast Cancer Challenge award, granted together with Novartis.

Japan

Talks initiated for validation before the PMDA. Prior recognition at BAILA-SHIBUYA.

Recognition and funding

2018
Applied Research Project
Origin of the technology development at UCSP.
2019
Formal start of R&D
Research on the microwave imaging system begins.
2020
World Bank Fund – ProCiencia
Funding for applied research.
2023
KOICA Funds
International cooperation from Korea.
2024
Novartis Award (Chile)
Breast cancer innovation challenge.
2024
First place at ESAN
Innovation recognition.
2024
Fundación Romero
Field deployment campaign.
2024
Clinical collaboration with AUNA and IREN-SUR
Start of joint clinical work.
2025
BAILA-SHIBUYA (Japan)
International recognition in the Japanese ecosystem.
2025
Lift UK Program – UC Innovation Center
Fellowship with a stay at the University of Cambridge.
2025
JICA Recognition
Japan International Cooperation Agency.
2025
Latam Health Champions (FIFARMA/INNOS)
Winners among 170+ innovations; mission to Boston: MIT, Harvard and Mass General.